Physicochemical properties of soy protein hydrolysate and its formulation and stability with encapsulated probiotic under  in vitro  gastrointestinal environment

2020 ◽  
Vol 85 (10) ◽  
pp. 3543-3551
Author(s):  
John S. Edwards ◽  
Navam S. Hettiarachchy ◽  
Thallapuranam Krishnaswamy Suresh Kumar ◽  
Franck Carbonero ◽  
Elizabeth M. Martin ◽  
...  
2012 ◽  
Vol 46 (1) ◽  
pp. 237-249 ◽  
Author(s):  
Cyril Roblet ◽  
Jean Amiot ◽  
Charles Lavigne ◽  
André Marette ◽  
Martin Lessard ◽  
...  

Foods ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 636 ◽  
Author(s):  
Marta Padial-Domínguez ◽  
F. Javier Espejo-Carpio ◽  
Raúl Pérez-Gálvez ◽  
Antonio Guadix ◽  
Emilia M. Guadix

The incorporation of lipid ingredients into food matrices presents a main drawback—their susceptibility to oxidation—which is associated with the loss of nutritional properties and the generation of undesirable flavors and odors. Oil-in-water emulsions are able to stabilize and protect lipid compounds from oxidation. Driven by consumers’ demand, the search for natural emulsifiers, such as proteins, is gaining much interest in food industries. This paper evaluates the in vitro emulsifying properties of protein hydrolysates from animal (whey protein concentrate) and vegetal origin (a soy protein isolate). By means of statistical modelling and bi-objective optimization, the experimental variables, namely, the protein source, enzyme (i.e., subtilisin, trypsin), degree of hydrolysis (2–14%) and emulsion pH (2–8), were optimized to obtain their maximal in vitro emulsifying properties. This procedure concluded that the emulsion prepared from the soy protein hydrolysate (degree of hydrolysis (DH) 6.5%, trypsin) at pH 8 presented an optimal combination of emulsifying properties (i.e., the emulsifying activity index and emulsifying stability index). For validation purposes, a fish oil-in-water emulsion was prepared under optimal conditions, evaluating its physical and oxidative stability for ten days of storage. This study confirmed that the use of soy protein hydrolysate as an emulsifier stabilized the droplet size distribution and retarded lipid oxidation within the storage period, compared to the use of a non-hydrolyzed soy protein isolate.


2017 ◽  
Vol 100 ◽  
pp. 268-276 ◽  
Author(s):  
Wenjie Xia ◽  
Han Zhang ◽  
Jingyao Chen ◽  
Hao Hu ◽  
Farruhbek Rasulov ◽  
...  

Author(s):  
Eisaku Iwasaki ◽  
Minoru Baba ◽  
Shuichi Kaminogawa ◽  
Atsushi Enomoto ◽  
Mamoru Totuka ◽  
...  

LWT ◽  
2017 ◽  
Vol 76 ◽  
pp. 259-269 ◽  
Author(s):  
Marcio Schmiele ◽  
Mária Herminia Ferrari Felisberto ◽  
Maria Teresa Pedrosa Silva Clerici ◽  
Yoon Kil Chang

2013 ◽  
Vol 3 (1) ◽  
pp. 37
Author(s):  
Melissa S. Munn ◽  
Shalamar Sibley ◽  
Richard Brundage ◽  
Baraem Ismail ◽  
Carrie P. Earthman

Background: Hypertension is considered the most prevalent cardiovascular disorder and a significant public health problem. A functional food that could potentially impede progression into a hypertensive state in pre-hypertensive individuals is of significant interest to clinicians and consumers. In vitro and animal studies suggest the presence of potential ACE inhibitory dairy-and soy-derived peptides. Very few human-based research studies have been conducted to investigate the blood pressure lowering and/or ACE-inhibitory effects of whey and soy protein hydrolysates in humans. This pilot study tested the acute effects of 20g doses of whey and soy hydrolysates in pre-hypertensive, overweight men and postmenopausal women on serum ACE activity and blood pressure. Findings: Using a randomized crossover design, four initial subjects received five treatments (unhydrolyzed casein, whey protein isolate, whey protein hydrolysate, soy protein isolate, soy protein hydrolysate) at different testing visits separated by three-day washout periods. Blood pressure and blood draws to measure ACE activity were taken at thirty minute intervals following treatment consumption. Both the soy protein and whey protein hydrolysates had notable in vitro ACE-inhibitory activity, both before and after heat treatment. No differences were observed among the protein treatments for either ACE activity or systolic blood pressure. Conclusions: The results of this pilot study support a discrepancy between in vitro and human-based in vivo ACE-inhibitory acute effects of whey and soy protein hydrolysates, underscoring the need for further research to better understand potential explanations for these findings.  Key Words: ACE (Angiotensin-converting enzyme), Casein, Soy, Whey, Protein, Blood pressure, Dairy, Bioactive, Peptides


Sign in / Sign up

Export Citation Format

Share Document